EV-to-FCF is calculated as enterprise value divided by its free cash flow. As of today, AN2 Therapeutics's Enterprise Value is $-19.78 Mil.
AN2 Therapeutics's Free Cash Flow for the trailing twelve months (TTM) ended in Dec. 2023 was $-53.29 Mil. Therefore, AN2 Therapeutics's EV-to-FCF for today is 0.37.
The historical rank and industry rank for AN2 Therapeutics's EV-to-FCF or its related term are showing as below:
ANTX'
s EV-to-FCF Range Over the Past 10 Years
Min: -12.41 Med: 0 Max: 0.51
Current: 0.37
During the past 4 years, the highest EV-to-FCF of AN2 Therapeutics was 0.51. The lowest was -12.41. And the median was 0.00.
ANTX's EV-to-FCF is ranked better than 77.35% of 393
companies
in the Biotechnology industry
Industry Median: 4.52
vs ANTX: 0.37
EV-to-FCF is a valuation multiple that allows analysts and investors to compare stocks, preferably in the same sector or industry. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio to determine the fair market value of a company.
The historical data trend for AN2 Therapeutics's EV-to-FCF can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Competitive Comparison of AN2 Therapeutics's EV-to-FCF
For the Biotechnology subindustry, AN2 Therapeutics's EV-to-FCF, along with its competitors' market caps and EV-to-FCF data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
AN2 Therapeutics's EV-to-FCF Distribution in the Biotechnology Industry
For the Biotechnology industry and Healthcare sector, AN2 Therapeutics's EV-to-FCF distribution charts can be found below:
* The bar in red indicates where AN2 Therapeutics's EV-to-FCF falls into.
AN2 Therapeutics's current Enterprise Value is $-19.78 Mil.
AN2 Therapeutics's Free Cash Flow for the trailing twelve months (TTM) ended in Dec. 2023 adds up the quarterly data reported by the company within the most recent 12 months, which was $-53.29 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
AN2 Therapeutics (NAS:ANTX) EV-to-FCF Explanation
EV-to-FCF is a valuation multiple that allows analysts and investors to compare stocks, preferably in the same sector or industry. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio to determine the fair market value of a company.
AN2 Therapeutics's PE Ratio for today is calculated as:
AN2 Therapeutics's share price for today is $2.535.
AN2 Therapeutics's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Dec. 2023 adds up the quarterly data reported by the company within the most recent 12 months, which was $-2.820.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Enterprise Value is used because it is a more complete measure in reflecting how much an investor pays when buying a company. Free Cash Flow is an important financial metric because it represents the actual amount of cash at a company's disposal. Companies with a low EV-to-FCF ratio, combined with a strong balance sheet are generally considered as undervalued.
AN2 Therapeutics EV-to-FCF Related Terms
Thank you for viewing the detailed overview of AN2 Therapeutics's EV-to-FCF provided by GuruFocus.com. Please click on the following links to see related term pages.
AN2 Therapeutics (AN2 Therapeutics) Business Description
AN2 Therapeutics Inc is a clinical-stage biopharmaceutical company developing treatments for rare, chronic, and serious infectious diseases with high unmet needs. The initial product candidate is epetraborole, a once-daily oral treatment for patients with chronic non-tuberculous mycobacterial, or NTM, lung disease.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
Portfolio Contest
ANTX has been successfully added to your 